US2016193329A1PendingUtilityA1

Deletion Mutants of Flagellin and Methods of Use

56
Assignee: VAXINNATE CORPPriority: Apr 18, 2008Filed: Nov 4, 2015Published: Jul 7, 2016
Est. expiryApr 18, 2028(~1.8 yrs left)· nominal 20-yr term from priority
Inventors:Langzhou SongLynda G. TusseyAlan R. ShawRobert S. BeckerYi ZhangScott UmlaufGe Liu
C07K 14/24A61K 2039/55555C07K 2319/75C12N 2760/16234C12N 2760/18571A61K 39/0275C07K 14/205C07K 14/005C07K 14/255C12N 2710/20034A61K 39/295C12N 2760/18522C12N 2770/24122A61P 31/14A61K 39/145C12N 7/00A61K 9/5153C07K 2319/40A61K 2039/55516C12N 2760/16162C12N 2760/16222C07K 14/11A61K 2039/6068A61P 31/04A61K 39/155A61K 9/127A61P 37/08A61K 2039/6031A61P 31/12C07K 14/32C07K 14/21A61P 37/04A61K 39/12C12N 2760/16271C07K 14/245C12N 2710/20071A61P 35/00C12N 2760/18534A61K 39/0005A61K 39/39C12N 2760/16171A61K 2039/55544C12N 2760/16134C12N 2770/24134C12N 2770/24171C12N 2760/16122C07K 19/00A61P 31/20C12N 2710/20022A61K 47/6937A61P 33/00A61K 39/00Y02A50/30
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions that include at least a portion of a flagellin and an antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to infection.

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . A method of stimulating an immune response in a subject, comprising the step of administering to the subject a composition that includes a protein that includes, in sequence, an amino-domain 0 of a flagellin protein, an amino-domain 1 of the flagellin protein, an amino-domain 2 of the flagellin protein, at least a portion of at least one pathogenic antigen that is non-native to flagellin, a carboxy-domain 2 of the flagellin protein, a carboxy-domain 1 of the flagellin protein and a carboxy-domain 0 of the flagellin protein, wherein the protein activates Toll-like Receptor 5. 
     
     
         3 . The method of  claim 2 , wherein the flagellin protein of the protein administered to the subject is at least one member selected from the group consisting of  Salmonella typhimurium  flagellin, an  E coli  flagellin, a  S. muenchen  flagellin, a  Yersinia  flagellin, a  P. aeruginosa  flagellin and a  L. monocytogenes  flagellin. 
     
     
         4 . The method of  claim 2 , wherein the protein administered to the subject further includes a linker between the pathogenic antigen and at least one of the amino-domain 2 of the flagellin protein and the carboxy-domain 2 of the flagellin. 
     
     
         5 . The method of  claim 4 , wherein the linker is an amino acid linker. 
     
     
         6 . The method of  claim 2 , wherein the flagellin protein of the protein administered to the subject has at least about 85% identity to the contiguous amino acid sequence as set forth in SEQ ID NO: 29. 
     
     
         7 . The method of  claim 2 , wherein the flagellin protein of the protein administered to the subject has at least about 90% identity to the contiguous amino acid sequence as set forth in SEQ ID NO: 29. 
     
     
         8 . The method of  claim 2 , wherein the flagellin protein of the protein administered to the subject has at least about 95% identity to the contiguous amino acid sequence as set forth in SEQ ID NO: 29. 
     
     
         9 . The method of  claim 2 , wherein the flagellin protein of the protein administered to the subject has at least 98% identity to the contiguous amino acid sequence as set forth in SEQ ID NO: 29. 
     
     
         10 . The method of  claim 2 , wherein the flagellin protein of the protein administered to the subject has at least 99% identity to the contiguous amino acid sequence as set forth in SEQ ID NO: 29. 
     
     
         11 . The method of  claim 2 , wherein the protein administered to the subject is associated with at least one particle. 
     
     
         12 . The method of  claim 11 , wherein the particle is a nanoparticle. 
     
     
         13 . The method of  claim 12 , wherein the nanoparticle is made from a lipid or other fatty acid. 
     
     
         14 . The method of  claim 2 , wherein the protein administered to the subject is associated with a liposome. 
     
     
         15 . The method of  claim 2 , wherein the protein administered to the subject is associated with a viral particle. 
     
     
         16 . The method of  claim 2 , wherein the protein administered to the subject further includes at least a portion of at least one additional antigen fused to the carboxy-domain 0 of the flagellin protein. 
     
     
         17 . The method of  claim 16 , wherein the one additional antigen is distinct from the pathogenic antigen between the amino-domain 2 and the carboxy-domain 2 of the flagellin protein of the protein administered to the subject. 
     
     
         18 . The method of  claim 16 , wherein the one additional antigen is similar to the pathogenic antigen between the amino-domain 2 and the carboxy-domain 2 of the flagellin protein of the protein administered to the subject. 
     
     
         19 . The method of  claim 16 , further including a linker between the additional antigen and the carboxy-domain 0 of the flagellin protein. 
     
     
         20 . The protein of  claim 19 , wherein the linker is an amino acid linker. 
     
     
         21 . The method of  claim 16 , wherein the additional antigen is a pathogenic antigen that is non-native to flagellin. 
     
     
         22 . The method of  claim 16 , wherein the protein administered to the subject is associated with at least one particle. 
     
     
         23 . The method of  claim 22 , wherein the particle is a nanoparticle. 
     
     
         24 . The method of  claim 23 , wherein the nanoparticle is made from a lipid or other fatty acid. 
     
     
         25 . The protein of  claim 16 , wherein the protein administered to the subject is associated with a liposome. 
     
     
         26 . The protein of  claim 16 , wherein the protein administered to the subject is associated with a viral particle. 
     
     
         27 . The method of  claim 2 , wherein the protein administered to the subject further includes at least a portion of at least one additional antigen fused to the amino-domain 0 of the flagellin protein. 
     
     
         28 . The method of  claim 27 , further including a linker between the additional antigen and the amino-domain 0 of the flagellin protein. 
     
     
         29 . The method of  claim 28 , wherein the linker is an amino acid linker. 
     
     
         30 . The method of  claim 27 , wherein the additional antigen is a pathogenic antigen that is non-native to flagellin. 
     
     
         31 . The method of  claim 27 , wherein the additional antigen is distinct from the pathogenic antigen between the amino-domain 2 and the carboxy-domain 2 of the flagellin protein. 
     
     
         32 . The method of  claim 27 , wherein the additional antigen is similar to the pathogenic antigen between the amino-domain 2 and the carboxy-domain 2 of the flagellin protein. 
     
     
         33 . The protein of  claim 27 , wherein the protein administered to the subject is associated with at least one particle. 
     
     
         34 . The protein of  claim 33 , wherein the particle is a nanoparticle. 
     
     
         35 . The protein of  claim 27 , wherein the nanoparticle is made from a lipid or other fatty acid. 
     
     
         36 . The protein of  claim 27 , wherein the protein administered to the subject is associated with a liposome. 
     
     
         37 . The protein of  claim 27 , wherein the protein administered to the subject is associated with a viral particle.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.